1/10

You can have metabolic dysfunction-associated steatotic liver disease (MASLD) for years without any obvious signs or symptoms. True or false?

  • True
  • False
2/10

Which of the following is NOT commonly associated with MASLD:

  • Overweight or obesity
  • High triglycerides
  • Diabetes or prediabetes
  • High HDL cholesterol
  • High blood pressure
3/10

What racial or ethnic group is most likely to develop MASLD?

  • Asian
  • Black
  • Hispanic or Latino
  • White
4/10

You have obesity and have MASLD. How much of your body weight do you need to lose to lower fat in your liver?

  • 3% to 5%
  • 7% to 10%
  • More than 20%
5/10

All types of MASLD cause liver inflammation and cell damage. True or false?

  • True
  • False
6/10

The main cause of death in people who have MASLD is:   

  • Liver failure
  • Cardiovascular disease
  • Liver cancer
7/10

A healthy lifestyle, which includes eating nutritious foods and exercising regularly, is the No. 1 way to stop MASLD from getting worse. True or false?

  • True
  • False
8/10

There are no medications approved to treat MASH.

  • True
  • False
9/10

Which nutrient deficiency is commonly associated with MASLD?

  • Iron
  • Magnesium
  • Vitamin A
  • Vitamin D
10/10

True or false: Most people with MASLD will need a liver transplant.

  • True
  • False

Show Sources

IMAGE PROVIDED BY:
1) Science Photo Library / Getty Images

SOURCES: 
Tinsay Ambachew Woreta, MD, assistant professor of medicine, Johns Hopkins University School of Medicine. 
National Institute of Diabetes and Digestive and Kidney Diseases: “Symptoms & Causes of NAFLD & NASH,” “Definition & Facts of NAFLD & NASH,” “Treatment for NAFLD & NASH,” “Diagnosis of NAFLD & NASH.” 
American Family Physician: “Nonalcoholic Fatty Liver Disease: Common Questions and Answers on Diagnosis and Management.” 
Cedars Sinai: “Non-alcoholic Fatty Liver Disease (NAFLD).” 
Transplantation: “Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.” 
Global Liver Institute: “Clinical Care Guidelines & Guidances in NAFLD/NASH.” 
Clinical Liver Disease: “Nonalcoholic Fatty Liver Disease and Cardiovascular Disease.” 
UpToDate: “Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH).” 
World Journal of Gastroenterology: “Nonalcoholic fatty liver disease and polycystic ovary syndrome.” 
American Liver Foundation: “NASH Definition & Prevalence.” 
Clinical and Experimental Hepatology: “Metabolic dysfunction-associated liver disease as a cardiovascular risk factor.” 
American Association For the Study of Liver Diseases: “New MASLD Nomenclature.”
Mayo Clinic New Network: “The silent liver disease experts warn is on the rise among Hispanics and children,” “Mayo Clinic Q and A: Weight Loss is Key to Combatting Nonalcoholic Fatty Liver Disease.” 
Albert Einstein College of Medicine: “Finding the Causes of Fatty Liver Disease in Latinos.”
Current Obesity Reports: “Nonalcoholic Fatty Liver Disease and Obesity Treatment.” 
FDA: “FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease.” 
International Journal of Preventative Medicine: “Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials.” 
Liver Research: “Vitamins and non-alcoholic fatty liver disease: A Molecular Insight.” 
Nutrients: “Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease: An Update.” 
Clinical Gastroenterology and Hepatology: “Racial and Ethnic Disparities in Non-alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.”
World Journal of Gastroenterology: “NAFLD prevalence differs among hispanic subgroups: The multi-ethnic study of atherosclerosis.”